Comment
. 2010 Apr 10;28(11):e173-4; author reply e175-6.
doi: 10.1200/JCO.2009.26.6148.
Epub 2010 Feb 22.
Predictors of benefit in colorectal cancer treated with cetuximab: are we getting "Lost in TranslationAL"?
- PMID: 20177018
- DOI: 10.1200/JCO.2009.26.6148
Item in Clipboard
Comment
Predictors of benefit in colorectal cancer treated with cetuximab: are we getting "Lost in TranslationAL"?
J Clin Oncol.
.
No abstract available
Comment on
-
Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab.J Clin Oncol. 2009 Oct 20;27(30):5068-74. doi: 10.1200/JCO.2008.21.3744. Epub 2009 Sep 8. J Clin Oncol. 2009. PMID: 19738126
Similar articles
-
KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature.J Clin Oncol. 2008 May 1;26(13):2228-30; author reply 2230-1. doi: 10.1200/JCO.2007.15.9186. J Clin Oncol. 2008. PMID: 18445856 No abstract available.
-
[Mutation of EGFR signaling pathway and therapy for metastatic colorectal cancer].Gan To Kagaku Ryoho. 2010 May;37(5):791-4. Gan To Kagaku Ryoho. 2010. PMID: 20495308 Japanese.
-
[Biology applied to cancer treatments: the example of colorectal cancer].Rev Prat. 2010 Oct 20;60(8):1100-2. Rev Prat. 2010. PMID: 21197742 French. No abstract available.
-
To give or not to give anti-epidermal growth factor receptor (EGFR) monoclonal antibodies to patients with KRAS G13D mutation in advanced colorectal cancer.Clin Colorectal Cancer. 2012 Jun;11(2):85-7. doi: 10.1016/j.clcc.2011.10.005. Epub 2011 Dec 9. Clin Colorectal Cancer. 2012. PMID: 22169039 Review. No abstract available.
-
[Gene mutation (KRAS, BRAF, PIK3CA) and clinical benefit of anti-EGFR antibody].Nihon Rinsho. 2011 Apr;69 Suppl 3:477-81. Nihon Rinsho. 2011. PMID: 22214007 Review. Japanese. No abstract available.
Cited by
-
EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan.Target Oncol. 2014 Sep;9(3):205-14. doi: 10.1007/s11523-013-0284-7. Epub 2013 Jul 3. Target Oncol. 2014. PMID: 23821377
-
Chemotherapy plus bevacizumab as an optimal first-line therapeutic treatment for patients with right-sided metastatic colon cancer: a meta-analysis of first-line clinical trials.ESMO Open. 2020 Mar;4(Suppl 2):e000605. doi: 10.1136/esmoopen-2019-000605. ESMO Open. 2020. PMID: 32132090 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
